Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyadenylate-binding protein-interacting protein 2B (PAIP2B) is a protein encoded by the PAIP2B gene in humans. PAIP2B functions primarily as a translational repressor by inhibiting the translation of capped and polyadenylated mRNAs; it achieves this by displacing the poly(A)-binding protein cytoplasmic 1 (PABPC1) from the poly(A) tail of mRNA. This, in effect, restricts PABP-mediated mRNA circularization and translation enhancement. PAIP2B is ubiquitously expressed in several human tissues (such as brain, liver, ovary, and others), and shares homology with PAIP2A, though it is slightly longer. Its physiological role is best characterized in early development, particularly in oocytes, while recent evidence implicates PAIP2B as a prognostic marker in pancreatic cancer due to its influence on cell proliferation, invasion, and tumor immune environment. PAIP2B also regulates the function of miRNAs, further linking it to disease progression in cancer. No direct drug interactions or safety concerns are described for PAIP2B.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyadenylate-binding protein-interacting protein 2B (PAIP2B).